Latest Insider Transactions at Royalty Pharma PLC (RPRX)
This section provides a real-time view of insider transactions for Royalty Pharma PLC (RPRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Royalty Pharma plc to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Royalty Pharma plc's insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jul 06
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
30,270
-2.38%
|
$1,271,340
$42.4 P/Share
|
|
Jun 30
2021
|
William E Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+11.66%
|
$37,453
$43.04 P/Share
|
|
Jun 30
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+3.85%
|
$37,453
$43.04 P/Share
|
|
Jun 30
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
871
+5.17%
|
$37,453
$43.04 P/Share
|
|
Jun 29
2021
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Indirect |
481,000
-6.12%
|
$19,721,000
$41.63 P/Share
|
|
Jun 28
2021
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Indirect |
167,448
-4.08%
|
$7,032,816
$42.11 P/Share
|
|
Jun 25
2021
|
Catherine M. Engelbert Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+23.03%
|
-
|
|
Jun 25
2021
|
Gregory Norden Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+10.21%
|
-
|
|
Jun 25
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+27.47%
|
-
|
|
Jun 25
2021
|
William E Ford Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+50.0%
|
-
|
|
Jun 25
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+21.5%
|
-
|
|
Jun 25
2021
|
Rory B Riggs Director |
SELL
Open market or private sale
|
Indirect |
666,464
-13.36%
|
$27,991,488
$42.75 P/Share
|
|
Jun 25
2021
|
Errol B Desouza Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+10.21%
|
-
|
|
Jun 25
2021
|
Ted W Love Director |
BUY
Grant, award, or other acquisition
|
Direct |
5,726
+20.03%
|
-
|
|
Jun 10
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
70,000
-3.82%
|
$3,220,000
$46.48 P/Share
|
|
Jun 08
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-3.79%
|
$2,300,000
$46.43 P/Share
|
|
Jun 08
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
70,000
-3.68%
|
$3,220,000
$46.48 P/Share
|
|
Jun 07
2021
|
Rory B Riggs Director |
BUY
Open market or private sale
|
Indirect |
273,650
+11.62%
|
$12,314,250
$45.26 P/Share
|
|
Jun 07
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-1.83%
|
$2,300,000
$46.79 P/Share
|
|
Jun 07
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
122,500
-3.15%
|
$5,635,000
$46.34 P/Share
|
|
Jun 07
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
16,568
-100.0%
|
$778,696
$47.02 P/Share
|
|
Jun 04
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100,000
-6.8%
|
$4,400,000
$44.6 P/Share
|
|
Jun 04
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
60,000
-3.79%
|
$2,640,000
$44.78 P/Share
|
|
Jun 04
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
16,566
-50.0%
|
$745,470
$45.13 P/Share
|
|
Jun 02
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
62,500
-3.13%
|
$2,625,000
$42.11 P/Share
|
|
Jun 02
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
50,000
-3.29%
|
$2,100,000
$42.13 P/Share
|
|
Jun 02
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
14,566
-30.54%
|
$597,206
$41.52 P/Share
|
|
May 21
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
100
-0.21%
|
$4,100
$41.0 P/Share
|
|
May 20
2021
|
Marshall Urist EVP, Research & Investments |
SELL
Open market or private sale
|
Direct |
1,900
-3.82%
|
$77,900
$41.08 P/Share
|
|
May 07
2021
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Indirect |
2,355,190
+50.0%
|
-
|
|
May 07
2021
|
Rory B Riggs Director |
BUY
Conversion of derivative security
|
Direct |
679,760
+50.0%
|
-
|
|
May 07
2021
|
George W. Lloyd EVP, Investments & CLO |
BUY
Conversion of derivative security
|
Indirect |
1,875,860
+47.74%
|
-
|
|
May 07
2021
|
Terrance P. Coyne EVP & CFO |
BUY
Conversion of derivative security
|
Indirect |
1,000,000
+50.0%
|
-
|
|
May 07
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
BUY
Conversion of derivative security
|
Indirect |
1,320,800
+46.48%
|
-
|
|
May 07
2021
|
Marshall Urist EVP, Research & Investments |
BUY
Conversion of derivative security
|
Direct |
49,700
+50.0%
|
-
|
|
May 07
2021
|
Legorreta Pablo G. CEO, Chairman of the Board |
BUY
Conversion of derivative security
|
Indirect |
2,325,000
+50.0%
|
-
|
|
Apr 14
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
55,714
-21.79%
|
$2,339,988
$42.1 P/Share
|
|
Apr 14
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
69,822
-21.81%
|
$2,932,524
$42.13 P/Share
|
|
Apr 12
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
359
-0.14%
|
$15,078
$42.32 P/Share
|
|
Apr 12
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
449
-0.14%
|
$18,858
$42.32 P/Share
|
|
Mar 31
2021
|
Henry A Fernandez Director |
BUY
Grant, award, or other acquisition
|
Direct |
816
+7.89%
|
$36,720
$45.9 P/Share
|
|
Mar 31
2021
|
Bonnie L Bassler Director |
BUY
Grant, award, or other acquisition
|
Direct |
816
+5.1%
|
$36,720
$45.9 P/Share
|
|
Mar 22
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
54,729
-9.75%
|
$2,517,534
$46.57 P/Share
|
|
Mar 22
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
43,927
-14.64%
|
$2,020,642
$46.32 P/Share
|
|
Mar 03
2021
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
100,000
-9.3%
|
$4,500,000
$45.37 P/Share
|
|
Mar 02
2021
|
Terrance P. Coyne EVP & CFO |
SELL
Open market or private sale
|
Indirect |
100,000
-12.7%
|
$4,700,000
$47.39 P/Share
|
|
Mar 02
2021
|
James F. Reddoch EVP & Chief Scientific Officer |
SELL
Open market or private sale
|
Indirect |
100,000
-12.64%
|
$4,700,000
$47.37 P/Share
|
|
Mar 02
2021
|
George W. Lloyd EVP, Investments & CLO |
SELL
Open market or private sale
|
Indirect |
125,000
-12.76%
|
$5,875,000
$47.37 P/Share
|
|
Feb 25
2021
|
Henry A Fernandez Director |
BUY
Open market or private purchase
|
Indirect |
25,700
+50.0%
|
$1,182,200
$46.83 P/Share
|
|
Dec 31
2020
|
George W. Lloyd EVP, Investments & CLO |
BUY
Conversion of derivative security
|
Indirect |
500,000
+50.0%
|
-
|